VALDOXAN® GRANTED MARKETING AUTHORISATION FOR THE TREATMENT OF MAJOR DEPRESSIVE EPISODES IN EUROPE

“There is still great scope for improved therapies to treat the devastating effects of depression”, said Professor Goodwin from Warneford Hospital, Oxford, United-Kingdom. “Valdoxan is an innovative, new approach to the management of depression that compares favourably to existing treatments. It has proven, sustained efficacy across a wide range of depressed patients, including those who are most severely depressed.”